Olivier Brandicourt Net Worth

The estimated Net Worth of Olivier Brandicourt is at least $53.2 Milion dollars as of 6 March 2013. Mr. Brandicourt owns over 113,364 units of Alnylam Pharmaceuticals Inc stock worth over $50,044,715 and over the last 12 years he sold ALNY stock worth over $3,190,063. In addition, he makes $0 as Director at Alnylam Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Brandicourt ALNY stock SEC Form 4 insiders trading

Olivier has made over 2 trades of the Alnylam Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 113,364 units of ALNY stock worth $3,190,063 on 6 March 2013.

The largest trade he's ever made was selling 113,364 units of Alnylam Pharmaceuticals Inc stock on 6 March 2013 worth over $3,190,063. On average, Olivier trades about 4,225 units every 0 days since 2012. As of 6 March 2013 he still owns at least 191,076 units of Alnylam Pharmaceuticals Inc stock.

You can see the complete history of Mr. Brandicourt stock trades at the bottom of the page.

Olivier Brandicourt biography

Olivier Brandicourt M.D. has been appointed as Director of the Company effective 3/2/2020. Dr. Brandicourt holds an Advanced Degree in Cellular and Immunological Pathophysiology from Paris Descartes University. He worked at the Institute of Infectious and Tropical Diseases at the Pitié-Salpêtrière Hospital in Paris with a focus on malaria research in West and Central Africa. Dr. Brandicourt formerly served as Chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) Board, is an Honorary Fellow of the Royal College of Physicians in London, and is a Board member of the National Committee on United States-China Relations in New York. Since December 2019 Dr. Brandicourt has also served as a Senior Advisor at Blackstone.

How old is Olivier Brandicourt?

Olivier Brandicourt is 64, he's been the Director of Alnylam Pharmaceuticals Inc since 2020. There are 6 older and 13 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.

What's Olivier Brandicourt's mailing address?

Olivier's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal a Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.

What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Complete history of Mr. Brandicourt stock trades at Alnylam Pharmaceuticals Inc, BeiGene Ltd a Pfizer

Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Maraganore,
  Chief Executive Officer, Director
• Jeffrey Poulton,
  Chief Financial Officer, Executive Vice President
• Laurie Keating,
  Executive Vice President, Chief Legal Officer, Secretary
• Yvonne Greenstreet,
  President, Chief Operating Officer
• Akshay Vaishnaw,
  President - Research and Development
• Dr. John M. Maraganore M.D., Ph.D.,
  CEO & Exec. Director
• Margaret Hamburg,
  Independent Director
• Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB,
  Pres, COO & Director
• Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA,
  Pres & COO
• Dr. Akshay K. Vaishnaw,
  Pres of R&D
• Jeffrey V. Poulton M.B.A.,
  CFO & Exec. VP
• Laurie Bartlett Keating J.D.,
  Exec. VP, Chief Legal Officer & Sec.
• Michael Bonney,
  Independent Chairman of the Board
• Phillip Sharp,
  Independent Director
• Marsha Fanucci,
  Independent Director
• Amy Schulman,
  Independent Director
• Steven Paul,
  Independent Director
• Colleen Reitan,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Michael W. Bonney B.A.,
  Exec. Chairman
• Olivier Brandicourt,
  Director
• Kevin Fitzgerald,
  Senior Vice President, Chief Scientific Officer
• Kelley Boucher,
  Chief Human Resource Officer, Senior Vice President
• Arianna Greco,
  Interim Chief Legal officer
• Mark Baglin,
  VP of Global Marketing
• Agnieszka Gallagher,
  Chief Ethics & Compliance Officer
• Christine Regan Lindenboom,
  Sr. VP of Investor Relations & Corp. Communications
• Dr. Alfred W. Boyle Ph.D.,
  Chief Technical Operations & Quality Officer
• David Alexandre C Gros,
  SVP, Chief Business Officer
• Kevin P Starr,
  Director
• Paul Schimmel,
  Director
• Sanofi,
  10% owner
• Michael Mason,
  VP, Finance and Treasurer
• John K Clarke,
  Director
• Barry E Greene,
  President
• Manmeet Singh Soni,
  Chief Financial Officer
• Carolyn R Bertozzi,
  Director
• Pushkal Garg,
  CMO & EVP Dev & Med Affairs
• Peter N Kellogg,
  Director
• Venture Management Co Iii L...,
  10% owner
• Victor J Dzau,
  Director
• Agnovartis Pharma Ag Novartis,
  
• Venture Management Co Iii L...,
  
• Peter Barrett,
  Director
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Ii Lp Chp,
  10% owner
• Kenneth S Koblan,
  Chief Scientific Officer
• Laurence Reid,
  SVP, Chief Business Officer
• Vicki L Sato,
  Director
• Management Ltd Abingworth,
  10% owner
• John A Jr Schmidt,
  SVP, Chief Scientific Officer
• Patricia L Allen,
  VP Finance and Treasurer
• Venture Fund V Lpatlas Vent...,
  
• John E Berriman,
  Director
• Vincent J Miles,
  Senior VP Business Development
• James L Vincent,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Edward M Scolnick,
  Director
• Tolga Tanguler,
  EVP, Chief Commercial Officer
• Charles Elliott Sigal,
  Director